{"id":63914,"date":"2025-04-30T21:14:13","date_gmt":"2025-04-30T21:14:13","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/63914\/"},"modified":"2025-04-30T21:14:13","modified_gmt":"2025-04-30T21:14:13","slug":"market-watch-animal-genetics-firm-genus-helps-blue-chips-extend-winning-streak-after-fda-win","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/63914\/","title":{"rendered":"MARKET WATCH: Animal genetics firm\u00a0Genus helps blue chips extend winning streak after FDA win"},"content":{"rendered":"<p class=\"author-section byline-plain\">By DAILY MAIL CITY &amp; FINANCE REPORTER <\/p>\n<p class=\"byline-section\"> Updated:  17:00 EDT, 30 April 2025   <\/p>\n<p class=\"mol-para-with-font\">Animal genetics firm Genus led the charge in London as the FTSE 100 clocked up a thirteenth day of gains despite a slump in the US economy.<\/p>\n<p class=\"mol-para-with-font\">Shares in FTSE 250-listed Genus jumped 16.1 per cent, or 256p, to 1842p after a key product won approval from the US Food and Drug Administration.<\/p>\n<p class=\"mol-para-with-font\">The wider market was also on the move with the FTSE 100 up 0.4 per cent, or 31.39 points, to 8494.85 and the FTSE 250 gained 0.4 per cent, or 74.87 points, to 19884.59.<\/p>\n<p class=\"mol-para-with-font\">The blue-chip index has risen for 13 days in a row, with the latest rise coming despite the US economy shrinking at an annual rate of 0.3\u00a0per cent in the first quarter.<\/p>\n<p class=\"mol-para-with-font\">Hip replacement maker Smith &amp; Nephew jumped 5.8 per cent, or 58p, to 1054p as a better-than-expected 3.1\u00a0per cent rise in first quarter revenues offset a tariff hit of up to \u00a315million.\u00a0<\/p>\n<p class=\"mol-para-with-font\">But miner Glencore fell 7.4 per cent, or 19.5p, to 244.4p after reporting a 30\u00a0per cent drop in first quarter copper production.<\/p>\n<p class=\"mol-para-with-font\">Taylor Wimpey expects lower profit margins in the first half of 2025, amid lower selling prices and rising <a style=\"font-weight: bold;\" target=\"_self\" href=\"https:\/\/www.thisismoney.co.uk\/money\/bills\/article-12412155\/What-inflation-falling-means-you.html\" id=\"mol-0b3ccf10-2602-11f0-a703-6b5c81dcbeab\" rel=\"noopener\">inflation<\/a> for builders. Shares lost 0.8 per cent, or 1p, to 117.45p.<\/p>\n<p>  <img decoding=\"async\" id=\"i-4bca6aa89b887dc9\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/97883481-14665595-Gene_therapy_Shares_in_FTSE_250_listed_Genus_jumped_16_1_after_a-a-4_1746045064924.jpeg\" height=\"412\" width=\"634\" alt=\"Gene therapy: Shares in FTSE 250-listed Genus jumped 16.1% after a key product won approval from the US Food and Drug Administration\" class=\"blkBorder img-share\" style=\"max-width:100%\" loading=\"lazy\" \/>  <\/p>\n<p class=\"imageCaption\">Gene therapy: Shares in FTSE 250-listed Genus jumped 16.1% after a key product won approval from the US Food and Drug Administration<\/p>\n<p>DIY INVESTING PLATFORMS<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/1746047651_370_A J Bell 2022_122X84.png\" alt=\"Easy investing and ready-made portfolios\" \/>AJ Bell<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/1746047651_370_A J Bell 2022_122X84.png\" alt=\"Easy investing and ready-made portfolios\" \/>AJ Bell<\/p>\n<p>Easy investing and ready-made portfolios<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/HL-Logo_122x84.jpg\" alt=\"Free fund dealing and investment ideas\" \/>Hargreaves Lansdown<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/HL-Logo_122x84.jpg\" alt=\"Free fund dealing and investment ideas\" \/>Hargreaves Lansdown<\/p>\n<p>Free fund dealing and investment ideas<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/ii_thisismoney_122x84.png\" alt=\"Flat-fee investing from \u00a34.99 per month\" \/>interactive investor<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/ii_thisismoney_122x84.png\" alt=\"Flat-fee investing from \u00a34.99 per month\" \/>interactive investor<\/p>\n<p>Flat-fee investing from \u00a34.99 per month<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/1746047653_985_122x84 Blue.png\" alt=\"Account and trading fee-free ETF investing\" \/>InvestEngine<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/1746047653_985_122x84 Blue.png\" alt=\"Account and trading fee-free ETF investing\" \/>InvestEngine<\/p>\n<p>Account and trading fee-free ETF investing<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/1746047653_358_T212Logo_Icon_130x90.png\n\" alt=\"Free share dealing and no account fee\" \/>Trading 212<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/1746047653_358_T212Logo_Icon_130x90.png\n\" alt=\"Free share dealing and no account fee\" \/>Trading 212<\/p>\n<p>Free share dealing and no account fee<\/p>\n<p class=\"tim-affiliate-text\">Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.<\/p>\n<p><a href=\"https:\/\/www.thisismoney.co.uk\/money\/diyinvesting\/article-1718291\/Pick-best-cheapest-investment-Isa-platform.html?ico=tim-affiliate_desktop_bottom-link-click\" target=\"_blank\" class=\"optional-btn-wrapper\" rel=\"noopener\">Compare the best investing account for you <\/a><\/p>\n<p>                    Share or comment on this article:<br \/>\n                        MARKET WATCH: Animal genetics firm\u00a0Genus helps blue chips extend winning streak after FDA win<\/p>\n","protected":false},"excerpt":{"rendered":"By DAILY MAIL CITY &amp; FINANCE REPORTER Updated: 17:00 EDT, 30 April 2025 Animal genetics firm Genus led&hellip;\n","protected":false},"author":2,"featured_media":63915,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3091],"tags":[51,2441,1232,1284,1283,16,15],"class_list":{"0":"post-63914","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-markets","10":"tag-money","11":"tag-moneymarkets","12":"tag-thisismoney","13":"tag-uk","14":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114428986420537160","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/63914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=63914"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/63914\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/63915"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=63914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=63914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=63914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}